Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Free Cash Flow (2019 - 2026)

Immunovant filings provide 7 years of Free Cash Flow readings, the most recent being -$92.3 million for Q4 2025.

  • Quarterly Free Cash Flow rose 8.2% to -$92.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$423.1 million through Dec 2025, down 29.92% year-over-year, with the annual reading at -$376.6 million for FY2025, 75.52% down from the prior year.
  • Free Cash Flow hit -$92.3 million in Q4 2025 for Immunovant, up from -$102.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$20.1 million in Q3 2021 and bottomed at -$117.4 million in Q2 2025.
  • Average Free Cash Flow over 5 years is -$61.0 million, with a median of -$57.8 million recorded in 2023.
  • The largest annual shift saw Free Cash Flow tumbled 210.2% in 2022 before it grew 28.01% in 2023.
  • Immunovant's Free Cash Flow stood at -$32.0 million in 2021, then tumbled by 45.43% to -$46.5 million in 2022, then fell by 1.58% to -$47.2 million in 2023, then tumbled by 112.94% to -$100.6 million in 2024, then grew by 8.2% to -$92.3 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Free Cash Flow are -$92.3 million (Q4 2025), -$102.5 million (Q3 2025), and -$117.4 million (Q2 2025).